Evidence map›Paper›PMID 34877937›Full record

ArticleJCI insight2021

Plasmin drives burn-induced systemic inflammatory response syndrome.

Breanne H Y Gibson, Colby C Wollenman, Stephanie N Moore-Lotridge, Patrick R Keller, J Blair Summitt, Alexey R Revenko, Matthew J Flick, Timothy S Blackwell, Jonathan G Schoenecker

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Role of Clot Formation and Plasminogen Activation in Lower Urinary Tract Pathologies.Arteriosclerosis, thrombosis, and vascular biology · 2025
    Review
  8. Deep insight into cytokine storm: from pathogenesis to treatment.Signal transduction and targeted therapy · 2025
    Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Breanne H Y GibsonDepartment of Pharmacology.
Colby C WollenmanSchool of Medicine.
Stephanie N Moore-LotridgeDepartment of Orthopaedic Surgery, Vanderbilt University Medical Center.
Patrick R KellerSchool of Medicine.
J Blair SummittDepartment of Plastic Surgery, Vanderbilt University Medical Center; and.
Alexey R RevenkoIONIS Pharmaceuticals Pulmonary and Oncology Drug Discovery, Carlsbad, California, USA.
Matthew J FlickDepartment of Pathology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA.
Timothy S BlackwellDepartment of Cancer Biology, Vanderbilt University, Nashville, Tennessee, USA.
Jonathan G SchoeneckerDepartment of Pharmacology.
Indiana University School of MedicineVanderbilt University Medical Center · USCzech Academy of Sciences, Institute of Microbiology · CZIonis Pharmaceuticals (United States) · USUniversity of North Carolina at Chapel Hill · USVanderbilt University · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8M
Interdisciplinary Training in Rheumatic DiseasesT32AR059039 · NIAMS · VANDERBILT UNIVERSITY · PI Tracy Minan Frech, AMY S MAJOR · 2010 to 2026
$4.3M
Severe Trauma Provokes Pathologic Continuum of Plasmin ActivationR01GM126062 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SCHOENECKER, JONATHAN · 2019 to 2023
$2.0M
The role of pathologic plasmin activity in trauma-induced systemic inflammatory response syndromeF31HL149340 · NHLBI · VANDERBILT UNIVERSITY · PI GIBSON, BREANNE HELEN YVONNE · 2019 to 2020
$60k
NCI NIH HHS P30 CA068485NHLBI NIH HHS F31 HL149340NIAMS NIH HHS T32 AR059039NIGMS NIH HHS R01 GM126062
6 · The paper itself

Abstract

Severe injuries, such as burns, provoke a systemic inflammatory response syndrome (SIRS) that imposes pathology on all organs. Simultaneously, severe injury also elicits activation of the fibrinolytic protease plasmin. While the principal adverse outcome of plasmin activation in severe injury is compromised hemostasis, plasmin also possesses proinflammatory properties. We hypothesized that, following a severe injury, early activation of plasmin drives SIRS. Plasmin activation was measured and related to injury severity, SIRS, coagulopathy, and outcomes prospectively in burn patients who are not at risk of hemorrhage. Patients exhibited early, significant activation of plasmin that correlated with burn severity, cytokines, coagulopathy, and death. Burn with a concomitant, remote muscle injury was employed in mice to determine the role of plasmin in the cytokine storm and inflammatory cascades in injured tissue distant from the burn injury. Genetic and pharmacologic inhibition of plasmin reduced the burn-induced cytokine storm and inflammatory signaling in injured tissue. These findings demonstrate (a) that severe injury-induced plasmin activation is a key pathologic component of the SIRS-driven cytokine storm and SIRS-activated inflammatory cascades in tissues distant from the inciting injury and (b) that targeted inhibition of plasmin activation may be effective for limiting both hemorrhage and tissue-damaging inflammation following injury.

Indexed as

AdolescentAdultAgedAged, 80 and overBurnsChildFemaleFibrinolysinHumansMaleMiddle AgedProspective StudiesSystemic Inflammatory Response SyndromeYoung AdultFibrinolysinCytokinesInflammationNF-kappaBPlasmin

Identifiers

PMID34877937
PMCPMC8675186
OpenAlexW4200081111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.